Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa

PLoS Medicine

Volumn 10, Issue 9, 2013, Pages

  Haberer, Jessica E ^a,b   Baeten, Jared M ^c   Campbell, James ^d   Wangisi, Jonathan ^d   Katabira, Elly ^e   Ronald, Allan ^f   Tumwesigye, Elioda ^g   Psaros, Christina ^a,b   Safren, Steven A ^a,b   Ware, Norma C ^b   Thomas, Katherine K ^c   Donnell, Deborah ^c,h   Krows, Meighan ^c   Kidoguchi, Lara ^c   Celum, Connie ^c   Bangsberg, David R ^a,b,i  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e MAKERERE UNIVERSITY   (Uganda)

^f UNIVERSITY OF MANITOBA   (Canada)

^g Kabwohe Clinical Research Center   (Uganda)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE; PLACEBO; TENOFOVIR;

ADULT; AFRICA; ALCOHOL CONSUMPTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COUNSELING; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MARRIAGE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); POLYGAMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUAL BEHAVIOR;

ADENINE; ADULT; AFRICA, EASTERN; ANTI-HIV AGENTS; COHORT STUDIES; DEOXYCYTIDINE; FAMILY CHARACTERISTICS; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; ORGANOPHOSPHONATES; REGRESSION ANALYSIS;

EID: 84884634016     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001511     Document Type: Article

References (34)

1. UNAIDS/WHO (2010) AIDS epidemic update. Available: http://www.unaids.org/globalreport. Accessed: 15 October 2012.
2. Padian NS, McCoy SI, Karim SS, Hasen N, Kim J, et al. (2011) HIV prevention transformed: the new prevention research agenda. Lancet 378: 269-278.
3. Baeten J, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367: 399-410.
4. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
5. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012) Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 367: 423-434.
6. Microbicide Trials Network (MTN) (2011) Statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. Available: http://www.mtnstopshiv.org/node/3619. Accessed 15 October 2012.
7. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. (2012) Preexposure prophylaxis for HIV infection among African women. N Engl J Med 367: 411-422.
8. Williams A, Friedland G, (1997) Adherence, compliance, and HAART. AIDS Clin Care 9: 51-58, 51-54, 58.
9. Kashuba ADM, Patterson KB, Dumond JB, Cohen MS, (2012) Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet 6736: 61852-61857.
10. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR, (2012) Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26: F13-F19.
11. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B,et al. (2013) Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, 3-6 March 2013; paper number 26LB.
12. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, et al. (2012) Emtricitabine- tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 4: 151ra25.
13. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ, (2008) "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials 9: 238-246.
14. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, et al. (2006) Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav 10: 227-245.
15. Hugen PW, Langebeek N, Burger DM, Zomer B, van Leusen R, et al. (2002) Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr 30: 324-334.
16. Liechty CA, Alexander CS, Harrigan PR, Guzman JD, Charlebois ED, et al. (2004) Are untimed antiretroviral drug levels useful predictors of adherence behavior? AIDS 18: 127-129.
17. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, et al. (2000) Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14: 357-366.
18. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, et al. (2004) Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 36: 1100-1102.
19. Psaros C (2011) An adherence intervention to support HIV pre-exposure prophylaxis (PrEP) adherence in serodiscordant couples in Uganda. 6th Annual International Conference on HIV Treatment and Prevention Adherence; Miami, 22-24 May 22-24; number 70065.
20. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, et al. (2008) Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5: e28 doi:10.1371/journal.pmed.0050028.
21. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
22. Filmer D, Pritchett LH, (2001) Estimating wealth effects without expenditure data-or tears: an application to educational enrollments in states of India. Demography 38: 115-132.
23. Cherpitel CJ, Ye Y, Bond J, Borges G, Cremonte M, et al. (2005) Cross-national performance of the RAPS4/RAPS4-QF for tolerance and heavy drinking: data from 13 countries. J Stud Alcohol 66: 428-432.
24. Bolton P, Wilk CM, Ndogoni L, (2004) Assessment of depression prevalence in rural Uganda using symptom and function criteria. Soc Psychiatry Psychiatr Epidemiol 39: 442-447.
25. Weiss HA, Wasserheit JN, Barnabas RV, Hayes RJ, Abu-Raddad LJ, (2008) Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol 5: 8.
26. Hahn JA, Woolf-King SE, Muyindike W, (2011) Adding fuel to the fire: alcohol's effect on the HIV epidemic in Sub-Saharan Africa. Curr HIV/AIDS Rep 8: 172-180.
27. Smith RM, Carrico AW, Montandon M, Kwena Z, Bailey R, et al. (2011) Attitudes and beliefs about anti-retroviral therapy are associated with high risk sexual behaviors among the general population of Kisumu, Kenya. AIDS Care 23: 1668-1675.
28. Pittman ME, Secura GM, Allsworth JE, Homco JB, Madden T, et al. (2011) Understanding prescription adherence: pharmacy claims data from the Contraceptive CHOICE Project. Contraception 83: 340-345.
29. Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, et al. (2012) What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr 59: 463-468.
30. Eyawo O, de Walque D, Ford N, Gakii G, Lester RT, et al. (2010) HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis 10: 770-777.
31. UNAIDS (2010) Getting to zero: 2011-2015 strategy. Available: https://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2010/JC2034_UNAIDS_Strategy_en.pdf. Accessed 28 January 2013.
32. Bangsberg DR, Hecht FM, Charlebois ED, Chesney M, Moss A, (2001) Comparing Objective measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav 5: 275-281.
33. Safren SA, Kumarasamy N, Hosseinipour M, Harwood MM, Hoffman I, et al. (2006) Perceptions about the acceptability of assessments of HIV medication adherence in Lilongwe, Malawi and Chennai, India. AIDS Behav 10: 443-450.
34. Haberer JE, Kahane J, Kigozi I, Emenyonu N, Hunt P, et al. (2010) Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav 14: 1340-1346.